Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary

International Journal of Gynecological Cancer

Volumn 18, Issue 2, 2008, Pages 379-383

  Jaishuen, A ^a,b   Berrios Rivera, J P ^a   Sirisabya, N ^a   Zheng, H G ^a   Li, Y ^a   Kavanagh, J J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Arthritis; Bevacizumab; Ovarian cancer; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; PACLITAXEL;

ADULT; ARTICLE; BLEEDING; CASE REPORT; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; INTESTINE PERFORATION; NEUTROPENIA; OSTEOARTHRITIS; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEINURIA; RECURRENT CANCER; WOUND HEALING IMPAIRMENT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYSTADENOCARCINOMA, SEROUS; FEMALE; HAND; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OSTEOARTHRITIS; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 40549104502     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01023.x     Document Type: Article

References (21)

1. Jemal A, Siegal R, Ward E et al. Cancer statistics. 2006. CA Cancer J Clin 2006 56 : 106 30.
2. Thigpen T. First-line therapy for ovarian carcinoma: what's next? Cancer Invest 2004 22 (Suppl. 2 21 8.
3. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003 361 : 2099 106.
4. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006 24 : 4699 707.
5. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 350 : 2335 42.
6. FDA approves bevacizumab (Avastin) as a first-line treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer in combination with platinum-based chemotherapy. Rockville, MD: U.S. Food and Drug Administration, 2006. Available at : http://www.fda.gov/cder/Offices/OODP/ whatsnew/bevacizumab200610.htm. Accessed January 18, 2007.
7. Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2006 102 : 140 4.
8. Cohn DE, Valmadre S, Resnick KE, Eaton LA, Copeland LJ, Fowler JM. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol 2006 102 : 134 9.
9. Wright JD, Hagemann A, Rader JS et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 2006 107 : 83 9.
10. Burger RA, Fleming GF. Carboplatin and paclitaxel with or without bevacizumab in treating patients with stage III or stage IV ovarian epithelial or primary peritoneal cancer, National Cancer Institute. Available at : http://www.clinicaltrials.gov/ct/show/NCT00262847. Accessed January 22, 2007.
11. Perren T, Oza AM. Chemotherapy with or without bevacizumab for ovarian cancer, primary peritoneal cancer or fallopian tube cancer (ICON 7). Available at : http://www.icon7trial.org/. Accessed January 22, 2007.
12. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin). a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005 333 : 328 35.
13. Kindler HL, Friberg G, Singh DA et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005 23 : 8033 40.
14. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 349 : 427 34.
15. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005 23 : 792 9.
16. Burger RA, Sill M, Monk BJ, Greer B, Sorosky J. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study [abstract 5009]. Proc ASCO 2005.
17. Garcia AA, Oza AM, Hirte H et al. Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: a California Cancer Consortium Trial [abstract 5000]. Proc ASCO 2005.
18. Cannistra SA, Matulonis U, Penson R et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer [abstract 5006]. Proc ASCO 2006.
19. Taxol (paclitaxel) injection. Rockville, MD: U.S. Food and Drug Administration, 1998. Available at : http://www.fda.gov/cder/foi/label/1998/ 20262s24lbl.pdf. Accessed January 18, 2007.
20. Giannakopoulos CK, Kyriakidou GK, Toufexi GE. Palmar fasciitis and polyarthritis associated with secondary ovarian carcinoma. Case report. Eur J Gynaecol Oncol 2005 26 : 339 41.
21. Martorell EA, Murray PM, Peterson JJ, Menke DM, Calamia KT. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg [Am] 2004 29 : 654 60.